What’s New
We share news about new product features, our thoughts on recent developments at MedaSystems or in the industry at large. Scroll down for a chronological view, or jump to posts using the categories to the left.
Beyond Patient Access: What New Neuro-Oncology Research Reveals About AI and Real-World Evidence
New research presented at the 2026 Society for Neuro-Oncology Annual Meeting highlights how AI can transform real-world data from Expanded Access Programs into valuable clinical insights. Discover how AI-powered analysis can uncover treatment patterns, improve data consistency, and help pharmaceutical companies unlock the potential of real-world evidence to support clinical research and program oversight.
The Hidden Cost of Complexity in Expanded Access: Why Operational Friction Matters to Patients
Operational complexity can create unnecessary delays in expanded access programs, affecting both healthcare providers and patients. Discover how streamlined workflows, centralized communication, and digital solutions can reduce administrative friction, improve coordination, and support more efficient patient access to investigational therapies.
Scaling Expanded Access: What Pharma Leaders Need to Prepare for Next
As Expanded Access Programs become more global and complex, pharmaceutical companies must rethink how they plan, coordinate, and scale. Explore key insights from industry leaders on supply planning, regulatory challenges, cross-functional collaboration, and the growing role of technology and AI in improving patient access to investigational therapies.
From Expanded Access to FDA Approval: What the Revolution Medicines Story Signals for Biopharma
Expanded Access programs often sit at the intersection of urgent patient need, regulatory complexity and operational readiness. The recent experience of Revolution Medicines offers a compelling example of how quickly that intersection can come into focus.
Five Years of MedaSystems: How Expanded Access Is Evolving—and What Comes Next
Expanded Access is evolving from a largely reactive process into a strategic, technology-enabled capability. Five years after MedaSystems was founded, we look at how automation, configurable workflows, real-world data, and emerging AI technologies are shaping the future of Expanded Access programs.
Expanding Access Worldwide: How MedaSystems Helps Bring Therapies to Patients Across the Globe
Expanded Access Programs help patients with serious or life-threatening conditions access investigational therapies when other treatment options are limited. Discover how MedaSystems helps pharmaceutical and biotechnology organizations centralize, automate and scale Expanded Access programs across patients, therapies and markets worldwide.
Why Excel and Email Are No Longer Enough for Global EAP and IIS Programs
As global EAP and IIS programs grow in scale and complexity, spreadsheets, email, and shared drives can create operational, security, and compliance risks. Discover why purpose-built, validated technology provides a more scalable, traceable, and controlled foundation for global programs.
OEAP West 2026 Recap: Expanded Access Enters a New Era of Operational Excellence
The conversations at Operationalize: Expanded Access Programs (OEAP) West in San Francisco made one thing abundantly clear: Expanded Access Programs (EAPs) are no longer viewed as exceptional, one-off initiatives.
The Biggest Challenges Facing Expanded Access Programs—and How Leading Pharmaceutical Companies Are Responding
As Expanded Access programs become more global and complex, pharmaceutical companies need scalable ways to manage requests, maintain compliance, and support patients faster.
Saving Lives Beyond Clinical Trials: How Expanded Access Programs Are Transforming Global Patient Care
For thousands of patients around the world, the difference between hope and heartbreak often comes down to time.
Build vs. Buy in Expanded Access Programs: Finding the Right Balance for Patient Access
As expanded access and managed access programs become increasingly important components of patient access strategy, biopharmaceutical companies face a critical question: which capabilities should be developed internally, and which are best supported through external expertise and technology partners?
Investigator-Initiated Studies (IIS) Trends in 2026
Investigator-Initiated Studies (IIS) are entering a transformative phase in 2026. As pharmaceutical companies, biotech firms, academic medical centers, and healthcare systems adapt to changing research demands, IIS programs are becoming more strategic, data-driven, patient-centered, and digitally enabled.
How Expanded Access Programs Are Evolving in 2026
For patients facing serious or life-threatening conditions, waiting for full regulatory approval of a promising therapy is often not an option. Expanded Access Programs (EAPs), sometimes referred to as compassionate use programs, have long provided a regulatory pathway for patients to receive investigational treatments outside of clinical trials.
Expanded Access in Oncology: From Exception to Strategy — and Why Infrastructure Now Matters
For decades, expanded access has been positioned as a last resort — a pathway reserved for patients who have exhausted all other options and cannot participate in clinical trials.
Why Expanded Access Programs Often Originate in Medical Affairs
Expanded Access Programs (EAPs) - also known as compassionate use—play a critical role in bridging the gap between clinical development and patient need.
Expanded Access Is Not Informal: Lessons from a Recent FDA Warning Letter
In a recent FDA warning letter involving investigational distribution practices, the agency cited failures tied to regulatory authorization and documentation requirements. The specific facts are unique to that company, but the broader lesson applies to every emerging biotech developing an investigational product.
Inside MedaSystems’ Expanded Access Platform—A Live Walkthrough of Configurable, Compliant Managed Access
See how MedaSystems helps sponsors streamline expanded access with configurable intake forms, automated routing, audited workflows, AI-powered PHI redaction, and a simple HCP portal experience.
Navigating the AI Frontier: How to Leverage Real-World Data to Advance Expanded Access Program Outcomes
Expanded Access Programs (EAPs) are a critical pathway for patients with serious or life-threatening conditions to access investigational therapies outside of clinical trials.
Lessons From the Field: What Expanded Access Teaches Us About Patients, Data, and Drug Development
Expanded access programs—sometimes called compassionate use—often enter a company’s world unexpectedly. A single request from a physician or patient can quickly become a defining moment that tests a company’s preparedness, values, and systems.
Agentic AI in Action: How Real AI Agents Are Helping EAP Teams and Physicians
Expanded access and compassionate use programs give patients vital pathways to investigational therapies, but they also introduce significant operational and regulatory complexity.